These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 8331526)

  • 1. Comparison between 6,7-dihydro-5H-dibenz(c,e)azepine and lovastatin as hypolipidemic agents in rats.
    Hall IH; Wong OT; Reynolds DJ; Simlot R
    J Pharm Sci; 1993 Jun; 82(6):565-70. PubMed ID: 8331526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypolipidemic activity of 6-substituted 6,7-dihydro-5H-dibenz[c,e]azepine and the effects of 6,7-dihydro-5H-dibenz[c,e]azepine on lipid metabolism of rodents.
    Hall IH; Murthy AR; Wyrick SD
    J Pharm Sci; 1986 Jun; 75(6):622-6. PubMed ID: 3735111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]).
    Bays HE; Dujovne CA; McGovern ME; White TE; Kashyap ML; Hutcheson AG; Crouse JR;
    Am J Cardiol; 2003 Mar; 91(6):667-72. PubMed ID: 12633795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The anti-inflammatory activity of 5H-dibenz[c,e]azepine-5,7(6H)dione, 6,7-dihydro-5H-dibenz[c,e]azepine, N-benzoylbenzamide and 1H-benz[d,e]isoquinoline-1,3(2H)dione derivatives in rodents.
    Hall IH; Simlot R; Oswald CB; Murthy AR; elSourady H; Chapman JM
    Acta Pharm Nord; 1990; 2(6):387-400. PubMed ID: 2095797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short-term efficacy and tolerability of combination therapy with lovastatin and acipimox in Chinese patients with type 2 diabetes mellitus and mixed dyslipidemia.
    Ko GT; Mak TW; Yeung VT; Chan DC; Lam CW; Tsang LW; Chow CC; Cockram CS
    J Clin Pharmacol; 1998 Oct; 38(10):912-7. PubMed ID: 9807971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of lovastatin on hepatic expression of the low-density lipoprotein receptor in nephrotic rats.
    Wei LX; Chen L; Wang WM; Zhang XH; Wu JB; Liang SF; Shu GY
    Genet Mol Res; 2014 Feb; 13(1):938-44. PubMed ID: 24634114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of policosanol and lovastatin on lipid profile and lipid peroxidation in patients with dyslipidemia associated with type 2 diabetes mellitus.
    Castaño G; Menéndez R; Más R; Amor A; Fernández JL; González RL; Lezcay M; Alvarez E
    Int J Clin Pharmacol Res; 2002; 22(3-4):89-99. PubMed ID: 12837046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of primary mixed hyperlipidemia with lovastatin.
    Vega GL; Grundy SM
    Arch Intern Med; 1990 Jun; 150(6):1313-9. PubMed ID: 2353864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of lovastatin and gemfibrozil in subjects with high ratios of total cholesterol to high-density lipoprotein cholesterol.
    Hung YJ; Pei D; Wu DA; Kuo SW; Fuh MM; Jeng C
    J Formos Med Assoc; 1999 Feb; 98(2):104-10. PubMed ID: 10083765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and pharmacological studies of 3-amino-2-methyl-1-phenyl-propanones as hypolipidemic agents in rodents.
    Huang Y; Hall IH
    Arch Pharm (Weinheim); 1996 Jul; 329(7):329-38. PubMed ID: 8764881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atherogenic risk reduction in patients with dyslipidaemia. comparison between bezafibrate and lovastatin.
    Sinzinger H; Pirich C; Kondor P; Etti H
    Eur Heart J; 1995 Nov; 16(11):1491-501. PubMed ID: 8881840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lovastatin versus bezafibrate for hyperlipemia treatment after heart transplantation.
    Hidalgo L; Zambrana JL; Blanco-Molina A; López-Granados A; Concha M; Casares J; Jiménez-Pérez J; López-Miranda J; Pérez-Jiménez F
    J Heart Lung Transplant; 1995; 14(3):461-7. PubMed ID: 7654731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toxicity of lovastatin in rats with experimentally induced nephrotic syndrome.
    Joven J; Vilella E; Camps J; Masana L; Turner PR; Simó JM; Villabona C
    Nephron; 1990; 56(4):399-404. PubMed ID: 2079999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypolipidemic activity of 3-amino-1-(2,3,4-mononitro-, mono-, or dihalophenyl)propan-1-ones in rodents.
    Huang Y; Hall IH
    Arch Pharm (Weinheim); 1996 Jul; 329(7):339-46. PubMed ID: 8764882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipid lowering effect of S-methyl cysteine sulfoxide from Allium cepa Linn in high cholesterol diet fed rats.
    Kumari K; Augusti KT
    J Ethnopharmacol; 2007 Feb; 109(3):367-71. PubMed ID: 16987625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Post-transplant hyperlipidaemia: low-dose lovastatin lowers atherogenic lipids without plasma accumulation of lovastatin.
    Gullestad L; Nordal KP; Forfang K; Ihlen H; Høstmark A; Berg KJ; Cheng H; Schwartz MS; Geiran O; Simonsen S
    J Intern Med; 1997 Dec; 242(6):483-90. PubMed ID: 9437409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of combining viscous fibre with lovastatin on serum lipids in normal human subjects.
    Agrawal AR; Tandon M; Sharma PL
    Int J Clin Pract; 2007 Nov; 61(11):1812-8. PubMed ID: 17935545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical evaluation of simvastatin in the treatment of hyperlipidemia].
    Lu ZL
    Zhonghua Xin Xue Guan Bing Za Zhi; 1993 Aug; 21(4):216-8, 253. PubMed ID: 8194433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipid-lowering effects of lovastatin in CAPD patients.
    Jacobs RH; Lal SM; Nolph KD
    Adv Perit Dial; 1993; 9():288-90. PubMed ID: 8105945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypolipidemic activity of 6-alkoxycarbonyl-3-aryl-1,3,5- triazabicyclo[3.1.0]hexane-2,4-diones and 2-alkoxycarbonyl-5-aryl-1,3,5-triazine-4,6(1H,5H)-diones in rodents.
    Izydore RA; Wong OT; Hall IH
    Lipids; 1993 Mar; 28(3):223-9. PubMed ID: 8464353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.